Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Pharmacokinetics and Initial Safety of Subcutaneous and Intramuscular Natalizumab in Subjects With Multiple Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Research Site
-
Scottsdale, Arizona, United States, 85259
- Research Site
-
-
California
-
Berkeley, California, United States, 94705
- Research Site
-
-
Colorado
-
Centennial, Colorado, United States, 80112
- Research Site
-
-
Florida
-
Maitland, Florida, United States, 32751
- Research Site
-
Vero Beach, Florida, United States, 32960
- Research Site
-
-
Illinois
-
Peoria, Illinois, United States, 61637
- Research Site
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48334
- Research Site
-
-
New York
-
Buffalo, New York, United States, 14203
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75214
- Research Site
-
Round Rock, Texas, United States, 78681
- Research Site
-
-
Virginia
-
Vienna, Virginia, United States, 22182
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- For arms 1,2,3 and 4: Diagnosis of Secondary Progressive Multiple Sclerosis (SPMS)
- For arms 5 and 6: Diagnosis of relapsing forms of Multiple Sclerosis (MS).
- No past history of receiving natalizumab.
Key Exclusion Criteria:
- For arms 1,2,3 and 4 Diagnosis of primary progressive MS or relapsing-remitting MS.
- Form arms 5 and 6: Diagnosis of primary progressive MS or secondary progressive MS without the occurrence of relapses.
NOTE: Other protocol defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: 1
Natalizumab IV (Participants with secondary progressive multiple sclerosis)
|
natalizumab
Other Names:
|
|
EXPERIMENTAL: 2
Natalizumab IM (Participants with secondary progressive multiple sclerosis)
|
natalizumab
Other Names:
|
|
EXPERIMENTAL: 3
Natalizumab SC (Participants with secondary progressive multiple sclerosis)
|
natalizumab
Other Names:
|
|
OTHER: 4
Standard of care as determined by the Investigator and Treating Neurologist (Participants with secondary progressive multiple sclerosis)
|
standard of care as determined by the Investigator and Treating Neurologist
|
|
EXPERIMENTAL: 5
Natalizumab SC (Participants with relapsing forms of multiple sclerosis)
|
natalizumab
Other Names:
|
|
EXPERIMENTAL: 6
Natalizumab IV (Participants with relapsing forms of multiple sclerosis)
|
natalizumab
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum observed concentration (Cmax) of natalizumab
Time Frame: Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
|
|
Time to maximum observed concentration (Tmax) of natalizumab
Time Frame: Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
|
|
Area under the curve to the last measurable concentration (AUC0-last) of natalizumab
Time Frame: Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
Area under the curve to the last measurable concentration as measured by the trapezoidal rule.
|
Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
|
Apparent volume of distribution of natalizumab
Time Frame: Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
|
|
Half-life of natalizumab
Time Frame: Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
|
|
Area under the curve extrapolated to infinity (AUC0-∞) of natalizumab
Time Frame: Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
|
|
Apparent Clearance of natalizumab
Time Frame: Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
Pre-dose, 4, 24, 48, 72 and 96 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
|
|
α4-integrin saturation
Time Frame: Pre-dose, 4, 24 and 72 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
PD activity will be assessed by measuring the degree of natalizumab saturation of the very late antigen-4 (also known as α4β1 integrin) VLA-4 (α4β1) receptor on peripheral blood lymphocyte/monocyte populations.
|
Pre-dose, 4, 24 and 72 hours post-dose and Days 7, 14, 21, 28, 35, 42 and 56
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with adverse events
Time Frame: 13-19 months
|
13-19 months
|
|
|
Number of participants with abnormalities in vital signs
Time Frame: 13-19 months
|
13-19 months
|
|
|
Number of participants with changes in the physical examination
Time Frame: 13-19 months
|
13-19 months
|
|
|
Number of participants with abnormal laboratory test results
Time Frame: 13-19 months
|
13-19 months
|
|
|
Number of participants with natalizumab antibodies
Time Frame: Days 28, 42, 56, Weeks 24 and 32
|
Days 28, 42, 56, Weeks 24 and 32
|
|
|
Change from Baseline in expanded disability status scale (EDSS)
Time Frame: Baseline, Weeks 8, 20, and 32
|
The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability.
Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.
|
Baseline, Weeks 8, 20, and 32
|
|
Change form Baseline in Multiple Sclerosis Functional Composite Scale (MFSC)
Time Frame: Baseline, Weeks 8, 20, and 32
|
The MFSC consists of 3 tests: 1. Timed 25-Foot Walk, a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet; 2. 9-Hole Peg Test (9HPT), a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs.
3. 3 Second Paced Auditory Serial Addition Test (PASAT 3).
The MSFC is based on the concept that scores for these 3 dimensions - arm, leg, and cognitive function are combined to create a single score that can be used to detect change over time.
A composite z-score is created, which represents the number of standard deviations (SDs) a participant's test result is higher (z > 0) or lower (z < 0) than the average test result (z = 0) of the reference population.
|
Baseline, Weeks 8, 20, and 32
|
|
Change from Baseline in Symbol Digit Modalities Test (SDMT)
Time Frame: Baseline, Weeks 8, 20, and 32
|
SDMT is a screening test for cognitive impairment.
Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key.
Scores range from 0 to 110 (best).
|
Baseline, Weeks 8, 20, and 32
|
|
Change from Baseline in visual analog scale (VAS)
Time Frame: Baseline, Weeks 8, 20, and 32
|
The participant's global assessment of well-being as assessed using a visual analogue scale (VAS) is a quality of life measurement that will be evaluated for the specified time periods.
Participants report how they feel on a scale of 0 to 100, where 0 indicates being "poor" and 100 being "excellent."
|
Baseline, Weeks 8, 20, and 32
|
|
Change from Baseline in visual function test
Time Frame: Baseline, Weeks 8, 20, and 32
|
Baseline, Weeks 8, 20, and 32
|
|
|
Number of new or newly enlarging T2 hyperintense lesions
Time Frame: Baseline and Week 32
|
Measured by magnetic resonance imaging (MRI).
|
Baseline and Week 32
|
|
Number of new gadolinium-enhanced lesions
Time Frame: Baseline and Week 32
|
Measured by magnetic resonance imaging (MRI).
|
Baseline and Week 32
|
|
Number of new T1 hypointense lesions
Time Frame: Baseline and Week 32
|
Measured by magnetic resonance imaging (MRI).
|
Baseline and Week 32
|
|
Whole brain atrophy
Time Frame: Baseline and Week 32
|
Atrophy will be measured as the percent brain volume change (PBVC) and will be assessed using the Structural Image Evaluation of Normalized Atrophy (SIENA).
|
Baseline and Week 32
|
|
Percent change in magnetization transfer ratio (MTR)
Time Frame: Baseline and Week 32
|
Remyelination will be measured using magnetization transfer ratio (MTR) in whole brain (WB) and normal-appearing brain tissue (NABT),
|
Baseline and Week 32
|
|
Diffusion tensor imaging (DTI)
Time Frame: Baseline and Week 32
|
Baseline and Week 32
|
|
|
Injection site pain assessment
Time Frame: Pre-dose, 5 and 15 minutes and 24 hours post-dose
|
Pre-dose, 5 and 15 minutes and 24 hours post-dose
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Physiological Effects of Drugs
- Immunologic Factors
- Natalizumab
Other Study ID Numbers
Other Study ID Numbers
- 101MS102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.